Hanmi is recognized as the No.1 R&D investing company in Korea, developing next generation Platform Technologies & new drugs in the fields of oncology, metabolic disorders and rare diseases. Hanmi has worked closely with global partners on various co-developments and collaborations. We are continuing to further expand through "Open Innovation Strategy" by finding potential partners for innovative solutions.